IgE CH3 peptide vaccine
AssigneePfizer Vaccines LLC
InventorsAlan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
Life of this patent
Estimating the term…
Abstract
The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
Claims16
An immunogen comprising at least one antigenic IgE peptide linked to an immunogenic carrier, wherein said antigenic IgE peptide consists of the amino acid sequence of SEQ ID NO:
- 220, and wherein no additional amino acid residues are present at either the C-terminus or N-terminus of said antigenic IgE peptide.
A composition comprising two immunogens wherein each of these immunogens consists of an antigenic IgE peptide individually conjugated to a Qbeta virus-like particle wherein:
- the first immunogen consists of the antigenic IgE peptide of SEQ ID No:
- 220 chemically cross linked to a Qbeta virus-like particle of SEQ ID NO:
- 435 via a thioether linkage using SMPH (Succinimidyl-6-[β-maleimidopropionamido]hexanoate) as cross linker, said linkage being between a lysine residue of the virus-like particle and the cysteine residue of said antigenic IgE peptide and;
- the second immunogen consists of the polypeptide of SEQ ID No:
- 457 chemically cross linked to a Qbeta virus-like particle of SEQ ID NO:
- 435 via a thioether linkage using SMPH (Succinimidyl-6-[β-maleimidopropionamido]hexanoate) as cross linker, said linkage being between a lysine residue of the virus-like particle and the cysteine residue of said polypeptide.
Dependencies are inferred from the claim text.